New radiation method aims to shield brain function during cancer treatment
NCT ID NCT05045950
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a special way of delivering whole-brain radiation called pulsed reduced dose-rate (PRDR) along with the drug memantine to help protect memory and thinking in people with brain metastases. About 53 adults with solid tumors that have spread to the brain will receive 30 Gy of radiation in 10 sessions using the PRDR technique. The main goal is to see if patients can complete the treatment as planned, with a focus on preserving neurocognitive function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pulsed reduced dose-rate whole-brain radiation therapy and memantine (Namenda)
What this could lead to
If successful, this approach could help preserve memory and thinking skills in patients needing whole-brain radiation for brain metastases.
What could go wrong
This is a small, early-phase trial with only 53 participants, so results may not apply broadly. The treatment may still cause cognitive decline or other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clement J. Zablocki Veterans Affairs Medical Center
RECRUITINGMilwaukee, Wisconsin, 53295, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Froedtert Hospital & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••